Compound information
- Natural Products
- ZC1986352
- Molecular Formula
- C24H27N5O3
- Molecular Weight
- 433.211389724 g/mol
- Structure
-
- IUPAC Name
- benzyl N-[(1R)-4-guanidino-1-(2-naphthylcarbamoyl)butyl]carbamate
- InChI
- InChI=1S/C24H27N5O3/c25-23(26)27-14-6-11-21(29-24(31)32-16-17-7-2-1-3-8-17)22(30)28-20-13-12-18-9-4-5-10-19(18)15-20/h1-5,7-10,12-13,15,21H,6,11,14,16H2,(H,28,30)(H,29,31)(H4,25,26,27)/t21-/m1/s1
- InChI Key
- IKWSULXYCUQIIT-OAQYLSRUSA-N
- SMILES
- NC(N)=NCCC[C@@H](NC(=O)OCc1ccccc1)C(=O)Nc1ccc2ccccc2c1
- Source
- ZINC000016997606
Warheads
- Carbamate
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 32 | Ring Count | 3 |
| Heteroatom Count | 8 | Rotatable Bond Count | 9 |
| Hydrogen Bond Acceptor Count | 4 | Hydrogen Bond Donor Count | 4 |
| Topological Polar Surface Area | 131.83 Å2 | LogP | 3.314 |
| LogS | -5.075 | LogD | 2.974 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.062 | Pgp substrate | 0.99 |
| HIA | 0.966 | F20 % | 0.961 |
| F30 % | 0.042 | Caco-2 | -5.852 |
| MDCK | -5.383 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.76 | PPB | 95.439 |
| VD | 1.498 | Fu | 1.18 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.089 | CYP1A2 substrate | 0.823 |
| CYP2A6 substrate | 0.693 | CYP2B6 substrate | 0.59 |
| CYP2C19 inhibitor | 0.034 | CYP2C19 substrate | 0.807 |
| CYP2C8 substrate | 0.822 | CYP2C9 inhibitor | 0.17 |
| CYP2C9 substrate | 1.0 | CYP2D6 inhibitor | 0.877 |
| CYP2D6 substrate | 0.952 | CYP2E1 substrate | 0.385 |
| CYP3A4 inhibitor | 0.08 | CYP3A4 substrate | 0.967 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.102 | CL | 3.831 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.961 | Hepatotoxicity | 0.91 |
| Mutagenicity | 0.939 | Rat Oral Acute Toxicity | 0.195 |
| FDAMDD | 0.744 | Skin Sensitization | 0.989 |
| Carcinogenicity | 0.016 | Eye Corrosion | 0.002 |
| Eye Irritation | 0.0 | Respiratory Toxicity | 0.885 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | -0.569 | IGC50 | 4.531 |
| LC50FM | 4.297 | LC50DM | 4.956 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.231 | NR-AR-LBD | 0.22 |
| NR-AhR | 0.751 | NR-Aromatase | 0.023 |
| NR-ER | 0.743 | NR-ER-LBD | 0.401 |
| NR-PPAR-gamma | 0.629 | SR-ARE | 0.708 |
| SR-ATAD5 | 0.634 | SR-HSE | 0.207 |
| SR-MMP | 0.349 | SR-p53 | 0.687 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.